Nor-NOHA

• Description :

  Nor-NOHA is a selective and reversible arginase inhibitor. nor-NOHA induces apoptosis in ARG2-expressing cells under hypoxia. nor-NOHA has anti-leukemic activity. nor-NOHA can used in study of endothelial dysfunction, immunosuppression and metabolism[1][2].

• CAS Number :

  [189302-40-7]

• Product Name Alternative :

  Nω-Hydroxy-nor-L-arginine

• UNSPSC :

  12352211

• Hazard Statement :

  H302-H315-H319-H335

• Target :

  Apoptosis; Arginase

• Type :

  Reference compound

• Related Pathways :

  Apoptosis; Immunology/Inflammation; Metabolic Enzyme/Protease

• Applications :

  Metabolism-protein/nucleotide metabolism

• Field of Research :

  Cancer; Metabolic Disease; Inflammation/Immunology

• Assay Protocol :

  https://www.medchemexpress.com/nor-noha.html

• Solubility :

  H2O : 250 mg/mL (ultrasonic)

• Smiles :

  O=C(O)[C@@H](N)CCNC(NO)=N

• Molecular Formula :

  C5H12N4O3

• Molecular Weight :

  176.17

• Precautions :

  P261-P264-P270-P271-P280-P302+P352-P304+P340-P305+P351+P338-P330-P362+P364-P403+P233-P405-P501

• References & Citations :

  [1]Ng KP, et al. The arginase inhibitor Nω-hydroxy-nor-arginine (nor-NOHA) induces apoptosis in leukemic cells specifically under hypoxic conditions but CRISPR/Cas9 excludes arginase 2 (ARG2) as the functional target. PLoS One. 2018 Oct 11;13 (10) :e0205254.|[2]Jung C, et al. Arginase inhibition mediates cardioprotection during ischaemia-reperfusion. Cardiovasc Res. 2010 Jan 1;85 (1) :147-54.

• Shipping Conditions :

  Room temperature

• Scientific Category :

  Reference compound1

• Clinical Information :

  Phase 1

• Citation 01 :

  Clin Immunol. 2024 Sep 3:110355.|Cell. 2025 Dec 11;188 (25) :7291-7308.e23.|FASEB J. 2025 Sep 30;39 (18) :e71057.|Front Cell Dev Biol. 2021 Dec 23;9:741911.